drugset / Trial / NCT00837915
Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions
RandomizedCrossoverOpen-label
Summary
The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets, in a fully replicated design, under fasting conditions.
Timeline
- Start
- 2002-06
- Primary completion
- 2002-08
- Completion
- 2002-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Loratadine | Small molecule | 10 mg | — |
| Subject | Pseudoephedrine | Small molecule | 240 mg | — |
Indications
No indication recorded.